The research company Nobelpharma is conducting the clinical trial Clinical Study of NPC-12Y Gel in Patients With Skin Lesions Associated With TSC.
The purpose of this study is to investigate the efficacy and safety of NPC-12Y gel compared with placebo for skin lesions associated with tuberous sclerosis.
It is planned to include 40 participants.
Actual study start date is June 1, 2022. The researchers expect to complete the study by September 30, 2024.
One primary outcome measure is Improvements in angiofibroma, Improvements comparing with baseline is assessed using photograph by IRC.
Further details can be found here https://ichgcp.net/clinical-trials-registry/NCT05495425.